Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | SLO | ENG

Naslov:Lynparza (olaparib) : novo tarčno zdravilo pri raku jajčnikov
Avtorji:ID Škof, Erik (Avtor)
ID Krajc, Mateja (Avtor)
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (455,09 KB)
MD5: 37B328CD7E07A7A79800651CD6B55CD1
PID: 20.500.12556/dirros/0a8348db-a511-405e-9e78-3dea12aebdba
 
Jezik:Slovenski jezik
Tipologija:1.04 - Strokovni članek
Organizacija:Logo OI - Onkološki inštitut Ljubljana
Ključne besede:rak jajčnikov, tarčna zdravila, kemoterapija, dedni raki
Leto izida:2016
Status objave pri reviji:Objavljeno
Verzija članka:Založnikova različica članka
Št. strani:str. 12-14
Številčenje:Letn. 20, št. 1
PID:20.500.12556/DiRROS-8145 Novo okno
UDK:618.1
ISSN pri članku:1408-1741
COBISS.SI-ID:2416763 Novo okno
Avtorske pravice:by Authors
Datum objave v DiRROS:03.01.2018
Število ogledov:3442
Število prenosov:800
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:AddThis
AddThis uporablja piškotke, za katere potrebujemo vaše privoljenje.
Uredi privoljenje...

Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Onkologija. strokovni časopis za zdravnike
Skrajšan naslov:Onkologija
Založnik:Onkološki inštitut
ISSN:1408-1741
COBISS.SI-ID:65324032 Novo okno

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:03.01.2018

Sekundarni jezik

Jezik:Angleški jezik
Naslov:Lynparza (olaparib) : New Mmedicine for targeted therapy of ovarian cancer
Povzetek:A new medicine for targeted treatment of patients with recurring serous ovarian or primary peritoneal serous carcinoma (PPSC), who have a mutation of BRCA1/2 genes (somatic mutation), was recently registered in the EU – LynparzaTM (olaparib). Olaparib was registered based on a subanalysis of a study in phase II (9), in which patients with BRCA1/2 gene mutation who received olaparib lived 7 months longer without the disease progressing than patients that were not administered this medicine (11 months vs. 4 months); the difference was statistically relevant (HR 0.18; p < 0.00001). There were no differences in total survival of patients. Olaparib is an oral medication in capsules, so patients can take it at home. The available data shows that the most frequent side effects were nausea and fatigue. 25% of patients took olaparib for two years or more and the therapy was rarely discontinued due to side effects (only 9% of patients), which shows that patients usually tolerate olaparib well, which is a great advantage compared to chemotherapy, which was so far the only available treatment for recurring ovarian cancer (9).


Arhiv

niGradiv

Nazaj